Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
As of close of business last night, Beam Therapeutics Inc’s stock clocked out at $21.38, down -1.02% from its previous closing price of $21.60. In other words, the price has decreased by -$1.02 from its previous closing price. On the day, 1.17 million shares were traded. BEAM stock price reached its highest trading level at $21.95 during the session, while it also had its lowest trading level at $21.15.
Ratios:
To gain a deeper understanding of BEAM’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.89 and its Current Ratio is at 5.89. In the meantime, Its Debt-to-Equity ratio is 0.18 whereas as Long-Term Debt/Eq ratio is at 0.16.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, JP Morgan on January 29, 2024, Upgraded its rating to Overweight and sets its target price to $40 from $38 previously.
On December 15, 2023, BofA Securities Downgraded its rating to Neutral which previously was Buy but kept the price unchanged to $35.
Jefferies Downgraded its Buy to Hold on December 08, 2023, whereas the target price for the stock was revised from $75 to $30.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 02 ’24 when Simon Amy sold 16,530 shares for $30.54 per share. The transaction valued at 504,851 led to the insider holds 70,060 shares of the business.
Evans John M. sold 18,102 shares of BEAM for $581,617 on Apr 01 ’24. The CEO now owns 1,058,343 shares after completing the transaction at $32.13 per share. On Apr 01 ’24, another insider, Simon Amy, who serves as the Chief Medical Officer of the company, sold 7,157 shares for $32.13 each. As a result, the insider received 229,954 and left with 86,590 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BEAM now has a Market Capitalization of 1759792000 and an Enterprise Value of 666556416. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.62 while its Price-to-Book (P/B) ratio in mrq is 1.78. Its current Enterprise Value per Revenue stands at 1.765 whereas that against EBITDA is -4.26.
Stock Price History:
The Beta on a monthly basis for BEAM is 1.87, which has changed by -0.30426294 over the last 52 weeks, in comparison to a change of 0.22363698 over the same period for the S&P500. Over the past 52 weeks, BEAM has reached a high of $49.50, while it has fallen to a 52-week low of $16.95. The 50-Day Moving Average of the stock is -33.68%, while the 200-Day Moving Average is calculated to be -21.83%.
Shares Statistics:
It appears that BEAM traded 1.53M shares on average per day over the past three months and 1943310 shares per day over the past ten days. A total of 81.63M shares are outstanding, with a floating share count of 67.88M. Insiders hold about 16.88% of the company’s shares, while institutions hold 78.29% stake in the company. Shares short for BEAM as of 1713139200 were 13173332 with a Short Ratio of 8.60, compared to 1710460800 on 14320311. Therefore, it implies a Short% of Shares Outstanding of 13173332 and a Short% of Float of 20.969999.
Earnings Estimates
A comprehensive evaluation of Beam Therapeutics Inc (BEAM) is underway, with the input of 12.0 analysts contributing to its current rating.On average, analysts expect EPS of -$1.42 for the current quarter, with a high estimate of -$1.18 and a low estimate of -$2.16, while EPS last year was -$1.33. The consensus estimate for the next quarter is -$1.38, with high estimates of -$1.18 and low estimates of -$2.19.
Analysts are recommending an EPS of between -$4.51 and -$8.85 for the fiscal current year, implying an average EPS of -$5.38. EPS for the following year is -$5.07, with 13.0 analysts recommending between -$3.47 and -$5.85.
